These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1273209)

  • 1. Sensory, perceptual, motor and cognitive functioning and subjective reports following oral administration of delta9-tetrahydrocannabinol.
    Peters BA; Lewis EG; Dustman RE; Straight RC; Beck EC
    Psychopharmacologia; 1976 May; 47(2):141-8. PubMed ID: 1273209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responses to oral delta9-tetrahydrocannabinol in frequent and infrequent marijuana users.
    Kirk JM; de Wit H
    Pharmacol Biochem Behav; 1999 May; 63(1):137-42. PubMed ID: 10340534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of delta9-tetrahydrocannabinol and cannabinol in man.
    Karniol IG; Shirakawa I; Takahashi RN; Knobel E; Musty RE
    Pharmacology; 1975; 13(6):502-12. PubMed ID: 1221432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC.
    Ménétrey A; Augsburger M; Favrat B; Pin MA; Rothuizen LE; Appenzeller M; Buclin T; Mangin P; Giroud C
    J Anal Toxicol; 2005; 29(5):327-38. PubMed ID: 16105257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of (-) trans-delta9-tetrahydrocannabinol, alone and in combination with ethanol, on human performance.
    Belgrave BE; Bird KD; Chesher GB; Jackson DM; Lubbe KE; Starmer GA; Teo RK
    Psychopharmacology (Berl); 1979 Mar; 62(1):53-60. PubMed ID: 108748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study investigating the acute dose-response effects of 13 mg and 17 mg Delta 9- tetrahydrocannabinol on cognitive-motor skills, subjective and autonomic measures in regular users of marijuana.
    Weinstein A; Brickner O; Lerman H; Greemland M; Bloch M; Lester H; Chisin R; Sarne Y; Mechoulam R; Bar-Hamburger R; Freedman N; Even-Sapir E
    J Psychopharmacol; 2008 Jun; 22(4):441-51. PubMed ID: 18635724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phytohemagglutinin-induced lymphocyte transformation in humans receiving delta9-tetrahydrocannabinol.
    Lau RJ; Tubergen DG; Barr M; Domino EF; Benowitz N; Jones RT
    Science; 1976 May; 192(4241):805-7. PubMed ID: 1265484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic interaction between cannabinol and delta9-tetrahydrocannabinol.
    Takahashi RN; Karniol IG
    Psychopharmacologia; 1975; 41(3):277-84. PubMed ID: 168604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration.
    Newmeyer MN; Swortwood MJ; Abulseoud OA; Huestis MA
    Drug Alcohol Depend; 2017 Jun; 175():67-76. PubMed ID: 28407543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effects of oral delta-9-tetrahydrocannabinol (THC) on autonomic cardiac activity and their relation to subjective and anxiogenic effects.
    Pabon E; Rockwood F; Norman GJ; de Wit H
    Psychophysiology; 2022 Feb; 59(2):e13955. PubMed ID: 34665890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects.
    Dalton WS; Martz R; Lemberger L; Rodda BE; Forney RB
    Clin Pharmacol Ther; 1976 Mar; 19(3):300-9. PubMed ID: 770048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study.
    ElSohly MA; deWit H; Wachtel SR; Feng S; Murphy TP
    J Anal Toxicol; 2001 Oct; 25(7):565-71. PubMed ID: 11599601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of interaction between delta9-tetrahydrocannabinol (delta-THC) and cannabidiol (CBD) in aggression, muscle control and body temperature experiments in mice.
    Ham MT; De Jong Y
    Psychopharmacologia; 1975; 41(2):169-74. PubMed ID: 1171491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of delta9-tetrahydrocannabinol on action potentials in the mollusc Aplysia.
    Acosta-Urquidi J; Chase R
    Can J Physiol Pharmacol; 1975 Oct; 53(5):793-8. PubMed ID: 1201484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
    Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans.
    Wachtel SR; ElSohly MA; Ross SA; Ambre J; de Wit H
    Psychopharmacology (Berl); 2002 Jun; 161(4):331-9. PubMed ID: 12073159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicinal Δ(9) -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests.
    Bosker WM; Kuypers KP; Theunissen EL; Surinx A; Blankespoor RJ; Skopp G; Jeffery WK; Walls HC; van Leeuwen CJ; Ramaekers JG
    Addiction; 2012 Oct; 107(10):1837-44. PubMed ID: 22553980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divided attention performance of cannabis users and non-users following cannabis and alcohol.
    Macavoy MG; Marks DF
    Psychopharmacologia; 1975 Oct; 44(2):147-52. PubMed ID: 1105631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans.
    Ranganathan M; Carbuto M; Braley G; Elander J; Perry E; Pittman B; Radhakrishnan R; Sewell RA; D'Souza DC
    Int J Neuropsychopharmacol; 2012 Oct; 15(9):1251-64. PubMed ID: 22243563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.